Qishen granules inhibit myocardial inflammation injury through regulating arachidonic acid metabolism.
Qishen granules (QSG), a traditional Chinese medicine, have been prescribed widely in the treatment of coronary heart diseases. Previous studies demonstrated that QSG had anti-inflammatory and cardio-protective effects in mice with acute myocardial infarction (AMI). However, the mechanisms by which QSG attenuate inflammation and prevent post-AMI heart failure (HF) are still unclear. In this study, we explored the anti-inflammatory mechanisms of QSG by in vitro and in vivo experiments. A novel inflammatory injury model of H9C2 cells was induced by lipopolysaccharide (LPS)-stimulated macrophage-conditioned media (CM). An animal model of AMI was conducted by ligation of left anterior descending (LAD) coronary artery in mice. We found that QSG inhibited release of cytokines from LPS-stimulated RAW 264.7 macrophages and protected H9C2 cardiac cells against CM-induced injury. In vivo results showed that QSG administration could improve cardiac functions and alter pathological changes in model of AMI. QSG regulated multiple key molecules, including phospholipases A2 (PLA2), cyclooxygenases (COXs) and lipoxygenases (LOXs), in arachidonic acid metabolism pathway. Interestingly, QSG also targeted TNF-α-NF-κB and IL-6-JAK2-STAT3 signaling pathways. Taken together, QSG achieve synergistic effects in mitigating post-AMI HF by regulating multiple targets in inflammatory pathways. This study provides insights into anti-inflammatory therapeutics in managing HF after AMI.
Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Chun
C
Li
Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Jing
J
Wang
Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Qiyan
Q
Wang
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China.
Yi
Y
Zhang
Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Na
N
Zhang
Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Linghui
L
Lu
Center of Scientific Experiment, Beijing University of Chinese Medicine, Beijing 100029, China.
Yan
Y
Wu
Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Qian
Q
Zhang
Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Wei
W
Wang
Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Yong
Y
Wang
Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Pengfei
P
Tu
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002460:Cell Line; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000009:adverse effects; D051379:Mice; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000209:etiology; D000067996:RAW 264.7 Cells; D051381:Rats
D000893:Anti-Inflammatory Agents; D016207:Cytokines; D004365:Drugs, Chinese Herbal; D008070:Lipopolysaccharides